US7305411099 - Common Stock
POINT BIOPHARMA GLOBAL INC
NASDAQ:PNT (12/26/2023, 7:10:43 PM)
After market: 12.51 +0.01 (+0.08%)12.5
+0.02 (+0.16%)
POINT Biopharma Global, Inc. is a radiopharmaceutical company. The company is headquartered in Indianapolis, Indiana and currently employs 129 full-time employees. The company went IPO on 2020-07-10. The firm is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The firm is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
POINT BIOPHARMA GLOBAL INC
4850 West 78th Street
Indianapolis INDIANA
P: 13175439957
CEO: Peter Kolchinsky
Employees: 129
Website: https://www.pointbiopharma.com/
The international market for radiopharmaceuticals is projected to exceed $13.67B by 2032, with a compound annual growth rate of 10.2% from 2023. Read more here.
Fusion Pharmaceuticals (FUSN) rises to a new 52-week high as Raymond James upgrades the biotech citing recent M&A activity in the radiopharma space. Read more here.
Eli Lilly completes its $1.4 billion acquisition of cancer drug developer Point Biopharma, solidifying its position in the pharmaceutical industry.
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a...
RBC Capital sees Bristol Myers' acquisition of RayzeBio as providing external validation for Fusion Pharmaceuticals' (FUSN) radiopharmaceutical approach. Read more here.
Eli Lilly's $1.4 billion acquisition of Point Biopharma set to close as tender offer for the radiopharmaceutical company successfully completed.
Here you can normally see the latest stock twits on PNT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: